BioPharma Drive: Drug Pricing
JUNE 10, 2025
The abrupt termination of the 17 panelists guiding the CDC’s vaccine recommendations could yield a new committee more aligned with Robert F. Kennedy Jr.’s skeptical views, analysts warned.
Chemical Biology and Drug Design
JUNE 9, 2025
A series of small molecule PD-L1 inhibitors was discovered via optimization of the solvent-interaction region. GJ19 showed the most potent anti-PD-L1 effects with an IC 50 of 32.06 nM. GJ19 (i.p., 15 mg/kg) effectively suppressed tumor growth with a TGI of 56.8% in a B16-F10 melanoma mouse model. ABSTRACT Despite extensive research, the topic of anti-PD-L1 small-molecule inhibitors remains elusive.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
JUNE 9, 2025
The landscape of genetic medicine is undergoing a profound transformation, driven by innovative approaches that challenge the traditional, disease-specific paradigms. One company leading the charge in this revolution is Alltrna , whose pioneering work in engineered transfer RNA (tRNA) therapeutics is offering new hope for patients with rare genetic diseases.
Covalent Modifiers
JUNE 12, 2025
Tibor Viktor Szalai, Vincenzo di Lorenzo, Nikolett Péczka, Levente M. Mihalovits, László Petri, Qirat F. Ashraf, Elvin D. de Araujo, Viktor Honti, Dávid Bajusz, and György M. Keserű ACS Medicinal Chemistry Letters 2025 16 (6), 991-997 DOI: 10.1021/acsmedchemlett.4c00622 The STAT family of transcription factors are important signaling hubs, with several of them, particularly STAT3, being emerging oncotargets already investigated in clinical trials.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Elrig
JUNE 12, 2025
Drug Discovery 101 – Webinar Recording Starting a career in drug discovery can feel overwhelming, but breaking down the process makes it more approachable. Our Drug Discovery 101 webinar outlines the entire process from start to finish. Here’s what you need to know to begin your journey in the field. The Basics of Drug Discovery Finding the Right Target The first step in drug discovery is all about identifying and confirming a target—something in the body that a drug can influence to impro
Chemical Biology and Drug Design
JUNE 11, 2025
We examined the quinolinequinones' ( QQ1- 7 ) effects on cancer cell lines. The most potent compound was QQ1 against ACHN cells with an IC50 value of 1.5 ± 0.16 μM. For better understanding, the effects of QQ1 on apoptosis, cell cycle, and oxidative stress were investigated. QQ1 inhibited ACHN cell proliferation via cell cycle arrest. The host-guest interactions of quinolinequinones were also studied in detail using thorough in silico docking simulations with pharmacokinetic studies.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drugs.com
JUNE 11, 2025
WEDNESDAY, June 11, 2025 -- The U.S. Food and Drug Administration has approved Widaplik (telmisartan, amlodipine, and indapamide) for the treatment of hypertension in adults.The combination pill is the first and only FDA-approved triple combination.
The Pharma Data
JUNE 13, 2025
Johnson & Johnson’s Dual-Targeting CAR T-Cell Therapy Shows Encouraging First Clinical Results in Large B-Cell Lymphoma Johnson & Johnson recently presented promising first-in-human data from its ongoing Phase 1b study evaluating JNJ-90014496 (JNJ-4496) — an investigational, dual-targeting, autologous chimeric antigen receptor (CAR) T-cell therapy — in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have not previously received a CAR T-cell therapy.
Broad Institute
JUNE 11, 2025
Broad Institute and Bayer extend their cardiovascular alliance By Leah Eisenstadt June 11, 2025 Breadcrumb Home Broad Institute and Bayer extend their cardiovascular alliance Partnership will continue with renewed focus on developing new cardiovascular therapies. By Broad Communications June 11, 2025 Related news Broad Institute and Bayer expand cardiovascular alliance Broad Institute of MIT and Harvard and Bayer Healthcare expand their partnership to develop therapies for cardiovascular disease
Collaborative Drug
JUNE 11, 2025
Compare top scientific data platforms for AI-driven drug discovery. Evaluate CDD Vault, Dotmatics, Benchling & more for chemistry and biologics workflows.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Science Daily: Pharmacology News
JUNE 11, 2025
Sea cucumbers, long known for cleaning the ocean floor, may also harbor a powerful cancer-fighting secret. Scientists discovered a unique sugar in these marine creatures that can block Sulf-2, an enzyme that cancer cells use to spread. Unlike traditional medications, this compound doesn t cause dangerous blood clotting issues and offers a cleaner, potentially more sustainable way to develop carbohydrate-based drugs if scientists can find a way to synthesize it in the lab.
The Pharma Data
JUNE 12, 2025
Bleximenib Shows Promise in AML When Combined with Venetoclax and Azacitidine, According to Johnson & Johnson’s Phase 1b Data Presented at EHA 2025 Johnson & Johnson today presented new and promising Phase 1b data demonstrating strong antileukemic activity and a favorable safety profile for bleximenib (JNJ-75276617) in combination with venetoclax (VEN) and azacitidine (AZA) in patients with acute myeloid leukemia (AML) who harbor KMT2A gene rearrangements (KMT2Ar) or NPM1 mutations (NPM1
Drugs.com
JUNE 12, 2025
THURSDAY, June 12, 2025 — A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization in U.S. infants. The U.S. Food and Drug Administration (FDA) has approved a monoclonal.
BioPharma Drive: Drug Pricing
JUNE 12, 2025
Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed CureVac in ongoing patent litigation.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Covalent Modifiers
JUNE 9, 2025
Charlotte M. Zammit, Cory M. Nadel, Ying Lin, Sajjan Koirala, Elnaz Ahani, Patrick Ryan Potts, and Daniel K. Nomura Journal of the American Chemical Society 2025 DOI: 10.1021/jacs.5c02801 Androgen-independent prostate cancers, correlated with heightened aggressiveness and poor prognosis, are caused by mutations or deletions in the androgen receptor (AR) or the expression of truncated variants of AR that are constitutively activated.
The Pharma Data
JUNE 12, 2025
EULAR 2025: Rilzabrutinib Shows Promise in IgG4-Related Disease — Reduction in Flares and Disease Activity Rilzabrutinib , a Bruton’s tyrosine kinase (BTK) inhibitor currently in clinical development, demonstrated a significant and sustained reduction in disease flares and key disease activity markers in patients with IgG4-related disease (IgG4-RD) , according to new data presented at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress in Barcelona, Spain (June 11–14).
Crown Bioscience
JUNE 11, 2025
The integration of patient tumor samples and mass spectrometry is reshaping the landscape of cancer research and precision medicine. As researchers and clinicians seek to understand the complexities of cancer at a molecular level, high-resolution analytical techniques have become essential. Mass spectrometry (MS), when applied to patient-derived tumor tissues, allows for comprehensive profiling of proteins, lipids, metabolites, and post-translational modifications—offering insights into tumor bi
Drugs.com
JUNE 9, 2025
MONDAY, June 9, 2025 — Prompt treatment with a drug combo can effectively manage chronic kidney disease in people with type 2 diabetes, a new clinical trial shows. Patients prescribed the combination of finerenone and empagliflozin.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
BioPharma Drive: Drug Pricing
JUNE 11, 2025
The company is paying $350 million upfront, and potentially over $1.3 billion overall, for a radiopharmaceutical for prostate cancer that works differently than Novartis’ Pluvicto.
The Pharma Data
JUNE 9, 2025
WuXi Biologics and VISEN Pharmaceuticals Expand Partnership to Localize Production of Lonapegsomatropin in China WuXi Biologics ,a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) services, and VISEN Pharmaceuticals (HKEX: 2561), a clinical-stage biopharmaceutical company dedicated to advancing endocrine disease treatments, have announced the formal launch of the technology transfer process for the commercial production of lonapegsomatropin.
Alta Sciences
JUNE 9, 2025
The Golden Era of GLP-1 Drugs: How Will it Impact Medicine and Society? by Dr. Gaetano Morelli MD, Chief Medical Officer and Executive Vice President Medical Affairs pmjackson Mon, 06/09/2025 - 15:32 Synopsis Dr. Morelli explores how rapid advancements in GLP‑1 therapies are transforming treatment paradigms, healthcare systems, and societal health outcomes.
Science Daily: Pharmacology News
JUNE 10, 2025
Scientists in Japan have discovered that a natural compound found in a type of ginger called kencur can throw cancer cells into disarray by disrupting how they generate energy. While healthy cells use oxygen to make energy efficiently, cancer cells often rely on a backup method. This ginger-derived molecule doesn t attack that method directly it shuts down the cells' fat-making machinery instead, which surprisingly causes the cells to ramp up their backup system even more.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
BioPharma Drive: Drug Pricing
JUNE 11, 2025
Skip to main content CONTINUE TO SITE ➞ Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.
The Pharma Data
JUNE 9, 2025
Jazz Pharmaceuticals Showcases Promising Phase 4 Results for Xywav® in Narcolepsy at SLEEP 2025, Underscoring Cardiovascular and Symptom Management Benefits Jazz Pharmaceuticals plc presented compelling new late-breaking data at the prestigious SLEEP 2025 conference, unveiling Phase 4 clinical results that further solidify the therapeutic benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in the management of narcolepsy.
New Drug Approvals
JUNE 11, 2025
Gepirone CAS 83928-76-1 BMY 13805, MJ 13805, ORG 13011, Gepirona, JW5Y7B8Z18 FDA 9/22/2023, Gepirone is indicated for the treatment of major depressive disorder (MDD) in adults Exxua Weight Average: 359.474 Monoisotopic: 359.232125194 Chemical Formula C 19 H 29 N 5 O 2 4,4-dimethyl-1-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}piperidine-2,6-dione Ingredient UNII CAS InChI Key Gepirone Hydrochloride 80C9L8EP6V 83928-66-9 DGOCVISYYYQFEP-UHFFFAOYSA-N Gepirone , sold under the brand name Exxua , is
Science Daily: Pharmacology News
JUNE 10, 2025
Acetaminophen may be doing more than just dulling pain in your brain it could be stopping it before it even starts. Scientists at Hebrew University have discovered that a metabolite of the drug, AM404, blocks pain signals right at their source by shutting down specific sodium channels in pain-sensing nerves. This radically shifts our understanding of how this common medication works and opens a door to new, more targeted painkillers that might eliminate side effects like numbness or weakness.
Drug Target Review
JUNE 13, 2025
As biomedical research evolves, the responsibility to align scientific progress with ethical practice evolves too. Dr. Liz Nunamaker, Executive Director of Global Animal Welfare at Charles River , is leading efforts to embed welfare, integrity and the 3Rs – replacement, reduction and refinement – into the heart of drug discovery and development. In this interview, she discusses her career path, the challenges of global standards and the practical impact of applying the 3Rs across research settin
The Pharma Data
JUNE 13, 2025
Mitsubishi Research Institute and Astellas Forge Collaborative Initiative to Support Japanese Drug Discovery Startups and Boost Global Innovation Mitsubishi Research Institute, Inc. (MRI) and Astellas Pharma Inc. (Astellas) today announced a significant new collaboration aimed at strengthening Japan’s role as a global hub for innovative drug discovery and fostering the growth of its biotechnology startups.
New Drug Approvals
JUNE 8, 2025
Ibuzatrelvir PF-07817883 CAS 2755812-39-4 Molecular Weight 489.49 Formula C 21 H 30 F 3 N 5 O 5 Ibuzatrelvir N -(Methoxycarbonyl)-3-methyl-L-valyl-(4 R )- N -[(1 S )-1-cyano-2-((3 S )-2-oxopyrrolidin-3-yl)ethyl]-4-(trifluoromethyl)-L-prolinamide PF 07817883 methyl N -[(2 S )-1-[(2 S ,4 R )-2-[[(1 S )-1-cyano-2-[(3 S )-2-oxopyrrolidin-3-yl]ethyl]carbamoyl]-4-(trifluoromethyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate KZ2X7QH2VT Ibuzatrelvir (development code PF-07817883 ) is an exper
Quanticate
JUNE 13, 2025
Clinical research generates vast amounts of diverse data from laboratory tests, patients, medical equipment, and outside sources. By organising and analysing this information, researchers can extract actionable insights that improve patient outcomes, data accuracy, drug efficacy and speed up trials.
Reprocell
JUNE 10, 2025
The Power of mRNA Reprogramming The emergence of mRNA reprogramming offers a precise, efficient, and xeno-free approach to generating induced pluripotent stem cells (iPSCs). These versatile cells hold immense potential for personalized medicine, disease modelling, and drug discovery. REPROCELL has led the way in mRNA reprogramming, in 2010 becoming the first company to commercialize mRNA-based reprogramming technologies.
The Pharma Data
JUNE 11, 2025
Bristol Myers Squibb Unveils Compelling Late-Breaking Phase 3 Data Highlighting the Efficacy of Sotyktu (Deucravacitinib) in Treating Psoriatic Arthritis Bristol Myers Squibb has announced new late-breaking clinical data from the pivotal Phase 3 POETYK PsA-1 trial, reinforcing the potential of its oral, selective TYK2 inhibitor, Sotyktu® (deucravacitinib) , as an effective treatment for adults with active psoriatic arthritis (PsA).
Expert insights. Personalized for you.
Let's personalize your content